Belite Bio (BLTE) Cash & Equivalents (2021 - 2025)

Belite Bio has reported Cash & Equivalents for 5 years, with the latest figure at $337.3 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents rose 964.78% year-over-year to $337.3 million; the trailing twelve-month figure through Dec 2025 stood at $337.3 million (up 964.78% YoY), and the FY2025 full-year result was $337.3 million, up 964.78% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $337.3 million, up from $31.7 million in the prior quarter.
• The five-year high for Cash & Equivalents was $337.3 million in Q4 2025, with the low at $17.3 million in Q4 2021.
• Average Cash & Equivalents over 5 years is $103.3 million, with a median of $42.1 million recorded in 2022.
• Year-over-year, Cash & Equivalents slumped 64.07% in 2024 and soared 964.78% in 2025.
• Tracing BLTE's Cash & Equivalents over 5 years: stood at $17.3 million in 2021, then soared by 142.67% to $42.1 million in 2022, then surged by 109.45% to $88.2 million in 2023, then tumbled by 64.07% to $31.7 million in 2024, then soared by 964.78% to $337.3 million in 2025.
• The last three Cash & Equivalents figures came in at $337.3 million (Q4 2025), $31.7 million (Q4 2024), and $88.2 million (Q4 2023), per Business Quant data.

Peer Comparison